Citations (26)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Hannah Asghari & Jeffrey Lancet. (2020) Liposomal encapsulated cytarabine and daunorubicin (CPX-351) for older patients with acute myeloid leukemia. Leukemia & Lymphoma 61:6, pages 1305-1312.
Read now
Read now
Lawrence D Mayer, Paul Tardi & Arthur C Louie. (2019) CPX-351: a nanoscale liposomal co-formulation of daunorubicin and cytarabine with unique biodistribution and tumor cell uptake properties. International Journal of Nanomedicine 14, pages 3819-3830.
Read now
Read now
Claudia Brunetti, Luisa Anelli, Antonella Zagaria, Giorgina Specchia & Francesco Albano. (2017) CPX-351 in acute myeloid leukemia: can a new formulation maximize the efficacy of old compounds?. Expert Review of Hematology 10:10, pages 853-862.
Read now
Read now
Articles from other publishers (23)
Reyhane Khademi, Zahra Mohammadi, Rahele Khademi, Amene Saghazadeh & Nima Rezaei. (2023) Nanotechnology-based diagnostics and therapeutics in acute lymphoblastic leukemia: a systematic review of preclinical studies. Nanoscale Advances 5:3, pages 571-595.
Crossref
Crossref
M. S. Sudheesh, K. Pavithran & Sabitha M. (2022) Revisiting the outstanding questions in cancer nanomedicine with a future outlook. Nanoscale Advances 4:3, pages 634-653.
Crossref
Crossref
Qi Wang, Paul Tardi, Nicole Sadowski, Sherwin Xie, Dennis Heller & Lawrence Mayer. (2020) Pharmacokinetics, drug metabolism, and tissue distribution of CPX-351 in animals. Nanomedicine: Nanotechnology, Biology and Medicine 30, pages 102275.
Crossref
Crossref
Yang Song, Xiangfu Guo, Jijun Fu, Bing He, Xueqing Wang, Wenbing Dai, Hua Zhang & Qiang Zhang. (2020) Dual-targeting nanovesicles enhance specificity to dynamic tumor cells in vitro and in vivo via manipulation of αvβ3-ligand binding. Acta Pharmaceutica Sinica B 10:11, pages 2183-2197.
Crossref
Crossref
Raffaele Palmieri, Giovangiacinto Paterno, Eleonora De Bellis, Lisa Mercante, Elisa Buzzatti, Fabiana Esposito, Maria Ilaria Del Principe, Luca Maurillo, Francesco Buccisano & Adriano Venditti. (2020) Therapeutic Choice in Older Patients with Acute Myeloid Leukemia: A Matter of Fitness. Cancers 12:1, pages 120.
Crossref
Crossref
Xiao Huang, Hai Lin, Feng Huang, Yuning Xie, Ka Hong Wong, Xiaoyu Chen, Dongyue Wu, Aiping Lu & Zhijun Yang. (2019) Targeting Approaches of Nanomedicines in Acute Myeloid Leukemia. Dose-Response 17:4, pages 155932581988704.
Crossref
Crossref
Sarah Bertoli, Suzanne Tavitian, Pierre Bories, Isabelle Luquet, Eric Delabesse, Thibault Comont, Audrey Sarry, Françoise Huguet, Emilie Bérard & Christian Récher. (2019) Outcome of patients aged 60‐75 years with newly diagnosed secondary acute myeloid leukemia: A single‐institution experience. Cancer Medicine 8:8, pages 3846-3854.
Crossref
Crossref
Marina S. Franco & Mônica C. Oliveira. (2019) Liposomes Co- encapsulating Anticancer Drugs in Synergistic Ratios as an Approach to Promote Increased Efficacy and Greater Safety. Anti-Cancer Agents in Medicinal Chemistry 19:1, pages 17-28.
Crossref
Crossref
Alessandra Iurlo, Daniele Cattaneo & Umberto Gianelli. (2019) Blast Transformation in Myeloproliferative Neoplasms: Risk Factors, Biological Findings, and Targeted Therapeutic Options. International Journal of Molecular Sciences 20:8, pages 1839.
Crossref
Crossref
Mario Luppi, Francesco Fabbiano, Giuseppe Visani, Giovanni Martinelli & Adriano Venditti. (2018) Novel Agents for Acute Myeloid Leukemia. Cancers 10:11, pages 429.
Crossref
Crossref
Andrew H. Wei & Ing S. Tiong. (2017) Midostaurin, enasidenib, CPX-351, gemtuzumab ozogamicin, and venetoclax bring new hope to AML. Blood 130:23, pages 2469-2474.
Crossref
Crossref
Prajwal Chaitanya Boddu, Hagop M. Kantarjian, Farhad Ravandi, Guillermo Garcia-Manero, Srdan Verstovsek, Elias J. Jabbour, Koichi Takahashi, Kapil Bhalla, Marina Konopleva, Courtney D. DiNardo, Maro Ohanian, Naveen Pemmaraju, Nitin Jain, Sherry Pierce, William G. Wierda, Jorge E. Cortes & Tapan M. Kadia. (2017) Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach. Cancer 123:16, pages 3050-3060.
Crossref
Crossref
Max J. Gordon, Paul Tardi, Marc M. Loriaux, Stephen E. Spurgeon, Elie Traer, Tibor Kovacsovics, Lawrence D. Mayer & Jeffrey W. Tyner. (2017) CPX-351 exhibits potent and direct ex vivo cytotoxicity against AML blasts with enhanced efficacy for cells harboring the FLT3-ITD mutation. Leukemia Research 53, pages 39-49.
Crossref
Crossref
Yossi Gilad, Michael A. Firer, Alex Rozovsky, Elena Ragozin, Boris Redko, Amnon Albeck & Gary Gellerman. (2014) “Switch off/switch on” regulation of drug cytotoxicity by conjugation to a cell targeting peptide. European Journal of Medicinal Chemistry 85, pages 139-146.
Crossref
Crossref
Yarong Liu, Jinxu Fang, Yu-Jeong Kim, Michael K. Wong & Pin Wang. (2014) Codelivery of Doxorubicin and Paclitaxel by Cross-Linked Multilamellar Liposome Enables Synergistic Antitumor Activity. Molecular Pharmaceutics 11:5, pages 1651-1661.
Crossref
Crossref
Georg Pabst, Norbert Kučerka, Mu-Ping Nieh & John KatsarasDavid Fenske & Pieter Cullis. 2014. Liposomes, Lipid Bilayers and Model Membranes. Liposomes, Lipid Bilayers and Model Membranes
291
316
.
Usama Gergis, Gail Roboz, Tsiporah Shore, Ellen Ritchie, Sebastian Mayer, Usama Wissa, Marshall McKenna, Paul Christos, Roger Pearse, Tomer Mark, Joseph Scandura, Koen van Besien & Eric Feldman. (2013) A Phase I Study of CPX-351 in Combination with Busulfan and Fludarabine Conditioning and Allogeneic Stem Cell Transplantation in Adult Patients with Refractory Acute Leukemia. Biology of Blood and Marrow Transplantation 19:7, pages 1040-1045.
Crossref
Crossref
Mark Wunderlich, Benjamin Mizukawa, Fu-Sheng Chou, Christina Sexton, Mahesh Shrestha, Yogen Saunthararajah & James C. Mulloy. (2013) AML cells are differentially sensitive to chemotherapy treatment in a human xenograft model. Blood 121:12, pages e90-e97.
Crossref
Crossref
Megan E. Godsey, Smruthi Suryaprakash & Kam W. Leong. (2013) Materials innovation for co-delivery of diverse therapeutic cargos. RSC Advances 3:47, pages 24794.
Crossref
Crossref
Jin Sun, Cong Luo, Yongjun Wang & Zhonggui He. (2013) The holistic 3M modality of drug delivery nanosystems for cancer therapy. Nanoscale 5:3, pages 845.
Crossref
Crossref
Ruth Duncan & María J. Vicent. (2013) Polymer therapeutics-prospects for 21st century: The end of the beginning. Advanced Drug Delivery Reviews 65:1, pages 60-70.
Crossref
Crossref
Ruth DuncanSimon C. W. Richardson. (2012) Endocytosis and Intracellular Trafficking as Gateways for Nanomedicine Delivery: Opportunities and Challenges. Molecular Pharmaceutics 9:9, pages 2380-2402.
Crossref
Crossref
Denis Buxton. 2011. Nanomedicine in Health and Disease. Nanomedicine in Health and Disease.